18 April 2016
Marinus Pharmaceuticals (NASDAQ:MRNS) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ganaxolone for the treatment of status epilepticus, according to the agency’s website. Status epilepticus is a dangerous condition in which epileptic seizures follow one another without recovery of consciousness between them. Ganaxolone has previously been given orphan drug designation for two other indications – as treatment for Protocadherin 19 (PCDH19) female epilepsy and as treatment for infantile spasms. MRNS shares closed at $5.17, with a 52-week range of $4.00 – $20.72.
The stock decreased 5.31% or $0.29 on April 14, hitting $5.17. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has declined 60.02% since September 9, 2015 and is downtrending. It has underperformed by 67.26% the S&P500.
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024